Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Updated mSMART guidelines for relapsed myeloma. This is a major revision: here.
First relapse: Options are BCMA CART, Tec-Dara, BCMA bispecific, or standard triplet. How to choose? See below.
Second relapse or later, belantamab is an additional option available.
For refractory myeloma, we have many options, and many more are upcoming.
For all the myeloma guidelines check out here.
For risk stratification and prognosis of all plasma cell disorders, check out here.”
Other articles featuring Vincent Rajkumar on OncoDaily.